FOLD Stock Rises on Settling Galafold Patent Dispute With Teva

Amicus Therapeutics (FOLD) announced that it has signed a licensing agreement with Teva Pharmaceuticals (TEVA) , which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold (migalastat) 123 mg capsules before the related patents expired. The stock jumped 14% on Thursday as investors cheered the dispute settlement with TEVA. Galafold, Amicus' lead marketed drug, is the fir ...